Meda AB

Last updated
Meda AB
FoundedJune 6, 1991;30 years ago (1991-06-06)
Headquarters,
Sweden
Revenue SEK 15 billion (2014)
Number of employees
5,202 (2014)
Parent Mylan
Divisions MedPointe

Meda AB is a specialty pharmaceutical company, headquartered in Solna, Sweden. Meda imports and markets pharmaceuticals, nutritional, and health-care products, and offers services including clinical research, registration, and logistics. At the end of 2014, Meda had 5,202 employees. Meda's pharmaceuticals are currently sold in more than 150 countries. [1]

Meda was listed on the Stockholm Stock Exchange until it was acquired by Mylan in 2016 through a cash and stock offer valued €7.2 million. [2]

Mergers, acquisitions and divestments

On 20 July 2007, Meda announced an $800 million cash-and-stock deal to buy the New Jersey-based pharmaceutical company MedPointe from a group of U.S. investors. MedPointe bought the diagnostics and drug businesses of Carter-Wallace in 2001, with the consumer product line going to Church & Dwight. [3] The deal was completed on 22 August with Meda entering the US market. The new shareholders in Meda are The Carlyle Group, The Cypress Group LLC, and other US investors, who had a combined shareholding in Meda of approximately 7%. [4]

In 2014, Meda acquired the Italian firm Rottapharm Madaus in order to add consumer health products to their portfolio. [5] Meda explored in 2015 the possibility of divesting its United States division, Meda Pharmaceuticals, to raise funds for expansion in other areas. [5]

Related Research Articles

An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.

AstraZeneca British-Swedish pharmaceutical company

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford-AstraZeneca COVID-19 vaccine.

Merck Group German chemicals and pharmaceuticals company

The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 57,000 employees and present in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies in the world.

Bristol Myers Squibb American pharmaceutical company

Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had total revenue of $39.3 billion.

AkzoNobel

Akzo Nobel N.V., stylized as AkzoNobel, is a Dutch multinational company which creates paints and performance coatings for both industry and consumers worldwide. Headquartered in Amsterdam, the company has activities in more than 80 countries, and employs over 32,000 people. Sales in 2020 were €8.5 billion.

Sanofi French pharmaceutical company

Sanofi S.A. is a French multinational pharmaceutical corporation headquartered in Paris, France, as of 2013 the world's fifth-largest by prescription sales. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products.

King Pharmaceuticals

King Pharmaceuticals, is a wholly owned subsidiary of Pfizer based in Bristol, Tennessee. Before being acquired by Pfizer, it was the world's 39th largest pharmaceutical company. On October 12, 2010, King was acquired by Pfizer for $14.25 per share. King produced a wide range of pharmaceuticals, including Altace for heart attack prevention, Levoxyl for hypothyroidism, Sonata, a sleeping aid, and Skelaxin, a muscle relaxant. King Pharmaceuticals operated manufacturing facilities in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin. They employed approximately 2,700 people including a sales force of over 1,000 individuals.

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

Perrigo Irish tax-registered pharmaceutical

Perrigo Company plc is an American Irish–registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the 6th-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes.

C.H. Boehringer Sohn AG & Ko. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

Qiagen

QIAGEN is a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding QIAGEN N.V., the company operates more than 35 offices in over 25 countries. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer. The main operative headquarters are located in Hilden, Germany.

Teva Pharmaceuticals Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd., also known as Teva Pharmaceuticals, is an Israeli multinational pharmaceutical company with headquarters in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Until 2020, Teva Pharmaceuticals was the largest generic drug manufacturer, when it was surpassed by US-based Pfizer. Teva is the overall eighteenth largest pharmaceutical company in the world.

Stada Arzneimittel

Stada Arzneimittel AG is a pharmaceutical company based in Bad Vilbel, Germany which specializes in the production of generic and over-the-counter drugs. In 2018, revenue totaled €2.33 billion.

Recipharm Swedish pharmaceutical manufacturer

Recipharm AB is one of the five largest pharmaceutical contract development and manufacturing organizations in the world, with production facilities in Sweden, France, Germany, Italy, Spain, Portugal, India and the UK as well as development sites in Sweden, Israel and the United States. The Swedish-based company employs around 9,000 people and operates over 30 facilities. The company provides pharmaceutical companies around the world with end-to-end development and manufacturing services, including a wide variety of dosage forms. Recipharm was listed on the Stockholm Stock Exchange in April 2014.

Bayer German pharmaceuticals company

Bayer AG is a German multinational pharmaceutical and life sciences company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals, seeds and biotechnology products. The company is a component of the Euro Stoxx 50 stock market index. Werner Baumann has been CEO since 2016.

Carter-Wallace American personal care company

Carter-Wallace was a personal care company headquartered in New York City. The company was formed by the merger of Carter Products and Wallace Laboratories. The company has a research facility in Cranbury, New Jersey.

Catalent American pharmaceutical company

Catalent, Inc. is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue.

Alvogen is an American pharmaceuticals company founded in 2009. In 2014 a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

Aurora Cannabis Inc. is a Canadian licensed cannabis producer, headquartered in Edmonton. It trades on the Toronto Stock Exchange and Nasdaq as ACB. As of late September 2018, Aurora Cannabis had eight licensed production facilities, five sales licences, and operations in 25 countries. It had a funded capacity of over 625,000 kilograms of cannabis production per annum with the bulk of capacity based in Canada and a growing presence in international markets, particularly Denmark and Latin America. Aurora is the second largest cannabis company in the world by market capitalization, after Canopy Growth Corporation. The company began trading on the NYSE on October 23, 2018 using the ticker ACB.

References

  1. "About Meda". Meda AB. Retrieved 15 August 2015.[ self-published source ]
  2. "Mylan compra Meda, affare da $7,2 miliardi". www.pharmastar.it. Retrieved 15 July 2021.
  3. https://www.cnbc.com/id/19864071
  4. https://www.globenewswire.com/news-release/2007/08/22/87789/0/en/Strategic-acquisition-of-MedPointe-Inc-completed.html
  5. 1 2 Ewing, Adam; Baigorri, Manuel (27 August 2015). "Swedish Drugmaker Meda Said to Weigh Sale of U.S. Operations". Bloomberg Business. Retrieved 28 August 2015.